Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy

Biochemical Pharmacology

Volumn 58, Issue 1, 1999, Pages 1-27

  Baizarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AIDS; Combination therapy; HIV resistance; Non nucleoside RT inhibitors (NNRTIs); Nucleoside RT inhibitors (NRTIs); Reverse transcriptase (RT)

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOVIRIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; PYRIDONE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TALVIRALINE; TENOFOVIR; TIPRANAVIR; TROVIRDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; CROSS RESISTANCE; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0033169086     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00029-5     Document Type: Note

References (219)

1. Balzarini J and De Clercq E, Analysis of inhibition of retroviral reverse transcriptase. Methods Enzymol 275: 472-502, 1996.
2. Balzarini J and De Clercq E, Biochemical pharmacology of nucleoside and non-nucleoside reverse transcriptase inhibitors active against HIV. In: Textbook of AIDS Medicine (Eds. Merigan TC, Bartlett JG and Bolognesi D), Chap. 47, pp. 815-847. Williams & Wilkins, Baltimore, MD, 1998.
3. Esnouf R, Ren JS, Ross C, Jones Y, Stammers D and Stuart D, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2: 303-308, 1995.
4. Spence RA, Kati WM, Anderson KS and Johnson KA, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 267: 988-993, 1995.
5. De Clercq E, HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 47: 155-169, 1994.
6. De Clercq E, Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 38: 2491-2517, 1995.
7. Fletcher RS, Syed K, Mithani S, Dmitrienko GI and Parniak MA, Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different medianistic forms of the enzyme. Biochemistry 34: 4346-4353, 1995.
8. Fletcher RS, Arion D, Borkow G, Wainberg MA, Dmitrienko GI and Pamiak MA, Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide non-nucleoside compounds. Biochemistry 34: 10106-10112, 1995.
9. Balzarini J, Pelemans H, Pérez-Pérez M-J, San-Félix A, Camarasa M-J, De Clercq E and Karlsson A, Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol Pharmacol 49: 882-890, 1996.
10. Balzarini J, Pelemans H, Karlsson A, De Clercq E and Kleim J-P, Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc Nad Acad Sci USA 93: 13152-13157, 1996.
11. Schapiro JM, Winters M and Merigan TC, Mutational analysis of the saquinavir high dose monotherapy study. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 73.
12. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson MP and Richman DD, High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171: 537-545, 1995.
13. Bacheler LT, Anton E, Jeffrey S, George H, Hollis G, Abremski A, and Sustiva Resistance Study Team, RT gene mutations associated with resistance to efavirenz. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 19.
14. Vasudevachari MB, Battista C, Lane HC, Psallidopoulos MC, Zhao B, Cook J, Palmer JR, Romero DL, Tarpley WG and Salzman NP, Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology 190: 269-277, 1992.
15. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J and De Clercq E, Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196: 576-585, 1993.
16. Kohlstaedt LA, Wang J, Friedman JM, Rice PA and Steitz TA, Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783-1790, 1992.
17. Arnold E, Jacobo-Molina A, Nanni RG, Williams RL, Lu X, Ding J, Clark AD, Zhang A, Ferris AL, Clark P, Hizi A and Hughes SH, Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature 357: 85-89, 1992.
18. Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Carlk P, Hizi A, Hughes SH and Arnold E, Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å shows bent DNA. Proc Nad Acad Sci USA 90: 6320-6324, 1993.
19. Patel PH, Jacobo-Molina A, Ding J, Tantillo C, Clark AD Jr, Raag R, Nanni RG, Hughes SH and Arnold E, Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry 34: 5351-5363, 1995.
20. Smerdon SJ, Jäger J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA and Steitz TA, Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Nad Acad Sci USA 91: 3911-3915, 1994.
21. Ren JS, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D and Stammers D, High resolution structure of HIV-1 RT: Insights from four RT-inhibitor complexes. Nat Struct Biol 2: 293-302, 1995.
22. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D and Stuart D, The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 3: 915-926, 1995.
23. Ding J, Das K, Tantillo C, Zhang W, Clark AD Jr, Jessen R, Lu X, Hsiou Y, Jacob-Molina A, Andries K, Pauwels R, Moereels H, Koymans L, Janssen PAJ, Smith RHJ Jr, Korege Koepke R, Michejda CJ, Hughes SH and Arnold E, Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure 3: 365-379, 1995.
24. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PAJ, Hughes SH and Arnold E, Structure of HIV-1 RT/ TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nat Struct Biol 2: 407-415, 1995.
25. Esnouf RM, Ren J, Hopkins AL, Ross AK, Jones EY, Stammers DK and Stuart DI, Unique features in the struture of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Nad Acad Sci USA 94: 3984-3989, 1997.
26. Hopkins AL, Ren J, Ensouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK and Stuart DI, Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 39: 1589-1600, 1996.
27. Nanni RG, Ding J, Jacobo-Molina A, Hughes SH and Arnold E, Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect Drug Discov Des 1: 129-150, 1993.
28. Stammers DK, Somers DO, Ross CK, Kirby I, Ray PH, Wilson JE, Norman M, Ren JS, Esnouf RM, Garman EF, Jones EY and Stuart DI, Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J Mol Biol 242: 586-588, 1994.
29. Hsiou Y, Clark AD Jr, Das K, Ding J, Boyer P, Hughes SH, Kleim J-P, Rösner M, Winkler I, Riess G and Arnold E, Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitory HBY 097. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 5.
30. Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI and Stammers DK, Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 37: 14394-14403, 1998.
31. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Gulp JS, Hellmig B, Woolf DJ, Debouck C and Harrison SC, The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Nad Acad Sci USA 92: 1222-1226, 1995.
32. Hsiou Y, Das K, Ding J, Clark AD Jr, Boyer PL, Janssen PAJ, Kleim J-P, Rösner M, Hughes SH and Arnold E, Crystal structures of wild-type and mutant HIV-1 reverse transcriptase and non nucleoside inhibitors: Implications for drug resistance mechanisms. Second Int Workshop on HIV Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 21.
33. Sarafianos SG, Kas K, Ding J, Clark AD Jr, Boyer PL, Hughes SH and Arnold E, Structures of Met184Ile and Met184Val mutants of HIV-1 reverse transcriptase with and without bound nucleic acid reveal template-primer repositioning and steric hindrance mechanism for lamivudine resistance. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 22.
34. Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PAJ, Boyer PL, Clark P, Smith RH Jr, Kroeger Smith MB, Michejda CJ, Hughes SH and Arnold E, Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 264: 1085-1100, 1996.
35. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih C-K, Myers M and Griffin J, Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 68: 1660-1666, 1994.
36. Kleim J-P, Winters M, Dunkler A, Suarez J-R, Riess G, Winkler I, Balzarini J, Oette D and Merigan T, Antiviral activity of the human immunodeficiency virus type 1 specific non-nucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. J Inject Dis 179: 709-713, 1999.
37. Witvrouw M, Pannecouque C, Erven K, Heens C, Van Remoortel B, Vandamme AM, Desmyter J and De Clercq E, Activity of non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-2 and SIV. Second Int Workshop on HIV Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 11.
38. Condra JH, Emini EA, Gotlib L, Graham DJ, Schlabach AJ, Wolfgang JA, Colonno RJ and Sardana VV, Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 36: 1441-1446, 1992.
39. Shih C-K, Rose JM, Hansen GL, Wu JC, Bacolla A and Griffin JA, Chimeric human immunodeficiency virus type-1/type-2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 88: 9878-9882, 1991.
40. Shaharabany M and Hizi A, The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J Biol Chem 267: 3674-3678, 1992.
41. Schinazi RF, Larder Ba and Mellors JW, Mutations in retroviral genes associated with drug resistance. Int Antiviral News 5: 129, 1997.
42. Menéndez-Arias L and Domingo E, Resistance tables for antiretroviral drugs. AIDS Cyber J 1: 95-127, 1998.
43. De Clercq E, Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: How to prevent the problem? Int J Antimicrob Agents 9: 21-36, 1997.
44. De Clercq E, In Search of a selective antiviral chemotherapy. Clin Microbiol Rev 10: 674-693, 1997.
45. De Clercq E, Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development. Med Res Rev 16: 125-157, 1996.
46. Larder BA, Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 75: 951-957, 1994.
47. Moyle GJ, Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Exp Opin Invest Drugs 6: 943-964, 1997.
48. Vandamme A-M, Van Vaerenbergh K and De Clercq E, Anti-human immunodeficiency virus drug combination strategies. Antiviral Chem Chemother 9: 187-203, 1998.
49. Balzarini J, Naesens L and De Clercq E, New antivirals-mechanism of action and resistance development. Curr Opin Microbiol 1: 535-546, 1998.
50. Larder BA and Kemp SD, Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158, 1989.
51. Larder BA, Coates KE and Kemp SD, Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 65: 5232-5236, 1991.
52. Kellam P, Boucher CA and Larder BA, Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 89: 1934-1938, 1992.
53. Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS and D'Aquila RT, Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38: 282-287, 1994.
54. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J and Wainberg MA, Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 38: 275-281, 1994.
55. Schinazi RF, Boudinot FD, Manouilov KK, Mellors JW, McMillan A, Schlueter-Wirtz S, Lloyd R Jr, Korba BE, Tennant B and Chu CK, Anti-HBV and anti-HIV activities of dioxolane-purine nucleosides. Ninth Int Conference on Antiviral Research, Urabandai, Fukushima, Japan, 1996, Abstract No. 20.
56. Mellors JW, Bazmi H, Chu CK and Schinazi RF, K65R mutation in HIV-1 reverse transcriptase causes resistance to (-)β-D-dioxolane-guanosine and reverses AZT resistance. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 7.
57. Foli A, Sogocio KM, Anderson B, Kavlick M, Saville MW, Wainberg MA, Gu Z, Cherrington JM, Mitsuya H and Yarchoan R, In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antiviral Res 32: 91-98, 1996.
58. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM and Wainberg MA, K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 39: 1888-1891, 1995.
59. Cherrington J, Chandok R, Mulato A, Lamy P, Mitsuya H and Wainberg M, In vitro selection and characterization of HIV-1 variants with reduced susceptibility to PMPA. Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 26.
60. Tisdale M, Parry NR, Cousens D, St. Clair MH and Boone LR, Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89). 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, 1994, Abstract No. 182, p. 92.
61. Tisdale M, Alnadaf T and Cousens D, Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 41: 1094-1098, 1997.
62. Harrigan R, Stone C, Griffin P, Bloor S, Tisdale M, Larder B and CNAA2001 Trial Team, Antiretroviral activity and resistance profile of the carbocyclic nucleoside HIV reverse transcriptase inhibitor 1592U89. Fourth Conference on Retroviruses and Opportunistic Infections, 22-26 January 1997, Washington, DC, USA, Abstract No. 15.
63. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ and Dubin DT, Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 36: 153-157, 1992.
64. Cherrington JM, Mulato AS, Fuller MD and Chen MS, Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers deceased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother 40: 2212-2216, 1996.
65. Mulato A, Lamy P, Li W, Miller M and Cherrington J, genotypic characterization of HIV-1 variants isolated from AIDS patients treated with adefovir dipivoxil (bis-POM PMEA). Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 24.
66. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD and Larder BA, Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557-1559, 1991.
67. Lacey SF and Larder BA, Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 38: 1428-1432, 1994.
68. Schinazi RF, Stuyver L, Wyseur A, Lloyd RMJ, Hough L, Rombout A, Rossau R and Rimland D, Proviral and plasma virus genotyping using a line probe assay in nucleoside treated HIV infected veterans affairs (VA) patients. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 65.
69. Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, Driscoll JS and Mitsuya H, In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-β-fluoro-2′,3′-dideoxyadenosine. Antimicrob Agents Chemother 41: 1313-1318, 1997.
70. Gu Z, Gao Q, Li X, Parniak MA and Wainberg MA, Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 66: 7128-7135, 1992.
71. Schinazi RF, Lloyd RM Jr, McMillan A, Gosselin G, Imbach J-L and Sommadossi J-P, Development of HIV-1 and SIV resistant to β-1-2′,3′-dideoxycytidine analogues. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 10.
72. Tisdale M, Kemp SD, Parry NR and Larder BA, Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90: 5653-5656, 1993.
73. Schinazi RF, Lloyd RM Jr, Nguyen M-H, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ and Mellors JW, Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 37: 875-881, 1993.
74. Harrigan PR, Tisdale M, Najera I, Cousens D, St. Clair M, Stone C, Kohli A, Myers R and Larder BA, Antiretroviral activity and resistance to 1592U89, a novel HIV RT inhibitor. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 16.
75. Gao Q, Gu Z, Pamiak MA, Cameron J, Cammack N, Boucher C and Wainberg MA, The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 37: 1390-1392, 1993.
76. Keulen W, Back NKT, van Wijk A, Boucher CA and Berkhout B, Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 71: 3346-3350, 1997.
77. Larder BA, Kemp SD and Harrigan PR, Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699, 1995.
78. Back N, Nijhuis M, Keulen W, Boucher C, Oude Essink B, van Kuilenburg A, van Gennip A and Berkhout B, Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15: 4040-4049, 1996.
79. Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R and Deacon NJ, Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol 46: 238-243, 1995.
80. Arnold E, Tantillo C, Boyer P, Ding J, Roy BM, Clark AD Jr, Pauwels R, Andries K, Janssen PAJ, Mellors J, Deacon N and Hughes SH, Implications of the three-dimensional structure of HIV-1 reverse transcriptase for resistance to antiviral drugs. Third Int Workshop on HIV Drug Resistance, Kauai, Hawaii, USA, 1994, Abstract No. 30.
81. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A and Larder BA, Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 70: 5930-5934, 1996.
82. Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E and Deacon NJ, An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 70: 8010-8018, 1996.
83. Demeter TM, Nawaz T, Morse S, Dolin R, Dexter A, Gerondelis P and Reichman RC, Development of zidovudine resistance mutations in patients receiving prolonged didanosine therapy. J Inject Dis 172: 1480-1485, 1995.
84. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T and Merigan TC, Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility by changes in infected individuals receiving dideoxyinosine monotherapy. Antimicrob Agents Chemother 41: 757-762, 1997.
85. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H, Lee A, Anderson R and Colonno RJ, Genotypic and phenotypic analysis of human immunodeficiency virus type 1 from patients on prolonged stavudine therapy. J Infect Dis 170: 1157-1164, 1994.
86. Bloor S, Hertogs K, Desmet RL, Pauwels R and Larder BA, virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 15.
87. Iversen AKN, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B and Merigan TC, Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70: 1086-1090, 1996.
88. Shirasaka T, Kavlick MF, Ueno T, Gao W-Y, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R and Mitsuya H, Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 92: 1-5, 1995.
89. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Katzenstein DA, Shafer RW and Merigan TC, Phenotypic and molecular analysis of HIV-1 isolates possessing 6 bp inserts in the reverse transcriptase gene that confer resistance to nucleoside analogues. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 16.
90. Whitcomb JM, Limoli K, Wrin T, Smith D, Tian H, ParkiN N, Lie YS and Petropoulos CJ, Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 17.
91. de Jong JJ, Jurriaans S, Goudsmit J, Baan E, Huismans R, Danner S, Hillebrand M, ten Veen JH and de WolF F, Insertion of two amino acids in reverse transcriptase (RT) during antiretroviral combination therapy: Implications for resistance against nucleoside RT inhibitors. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 18.
92. Schmit JC, Vanderlinden I, Ruiz L, Clotet B, Hermans S, Sprecher S, Arendt V, Peetermans W, Harrer T, Vaira D, Desmyter J, De Clercq E and Vandamme A-M, Prevalence of multi-drug resistance to dideoxynucleoside (ddN) analogues in patients on ddN combination therapy. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 39.
93. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede V, Rimland D, Schinazi RF and Rossau R, Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41: 284-291, 1997.
94. Kemp S and Bloor S, Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance. Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 11.
95. Yvon A, Calvez V, Valantin M-A, Mouroux M, Bossi P, Coutellier A, Bonmarchand M, Delaugerre C, Katlama C and Huraux J-M, Multidrug-resistance mutations to dideoxynucleoside (ddN) analogues can be associated with classical zidovudine resistance mutations. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 27.
96. Shafer RW, Iversen AK, Winters MA, Aguiniga E, KatzenStein DA and Merigan TC, Drug resistance and heterogeneous long-term virologie responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 172: 70-78, 1995.
97. Ueno T, Shirasaka T and Mitsuya H, Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem 270: 23605-23611, 1995.
98. Maeda Y, Venzon DJ and Mitsuya H, Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multidideoxynucleoside resistance. J Infect Dis 177: 1207-1213, 1998.
99. Balzarini J, Dunkler A, Pelemans H, De Clercq E and Kleim J-P, Combination of the multidrug resistance mutation Q151 M/L and the AZT resistance mutation T215Y/F in the same HIV-1 reverse transcriptase is compatible with enzymatic activity. 2. Clinical science. Proceedings of The 12th World AIDS Conference, Geneva, Switzerland, 28 June-3 July 1998, pp. 319-323. Monduzzi Editore, Bologna, Italy, 1998.
100. Mellors J, Bazmi H, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J and Mayers D, Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 39: 1087-1092, 1995.
101. Tachedjian G, Hooker DJ, Gurusinghe AD, Bazmi H, Deacon NJ, Mellors J, Birch C and Mills J, Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212: 58-68, 1995.
102. Tachedjian G, Mellors J, Bazmi H, Birch C and Mills J, zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol 70: 7171-7181, 1996.
103. Prasad VR, Lowy I, de los Santos T, Chiang L and Goff SP, Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 88: 11363-11367, 1991.
104. Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, Hsiou Y, Arnold E and Riess G, Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-Val or Ile and Val-75-Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA 93: 34-38, 1996.
105. Boyer PL, Gao H-Q and Hughes SH, A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 42: 447-452, 1998.
106. Byrnes VW, Sardana W, Schleif WA, Condra JH, Waterbury JA, Wolfgang JA, Long WJ, Schneider CL, Schlabach AJ, Wolanski BS, Graham DJ, Gotlib L, Rhodes A, Titus DL, Roth E, Blahy OM, Quintero JC, Staszewski S and Emini EA, Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 37: 1576-1579, 1993.
107. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih C-K, Myers M and Griffin J, Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 68: 1660-1666, 1994.
108. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J, Tarpley WG and De Clercq E, Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells by combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol 67: 5353-5359, 1993.
109. Vasudevachari MB, Battista C, Lane HC, Psallidopoulos MC, Zhao B, Cook J, Palmer JR, Romero DL, Tarpley WG and Salzman NP, Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology 190: 269-277, 1992.
110. Buckheit JRW, Fliakas-Boltz V, Decker WD, Roberson JL, Stup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR and Bader JP, Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res 26: 117-132, 1995.
111. Winslow DL, Garber S, Reid C, Scarnati H, Korant B, Emini E and Anton ED, Development of high-level resistance to DMP 266 requires multiple mutations in the reverse transcriptase gene. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 13.
112. Winslow DL, Reid C, Garber S, Scamati H, Rayner M and Anton E, Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 10.
113. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen I-W, Schleif WA, Sardana VV, Long WJ, Byrnes VW and Emini EA, L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39: 2602-2605, 1995.
114. Richman DD, Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 37: 1207-1213, 1993.
115. Larder BA, 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 36: 2664-2669, 1992.
116. Mellors JW, Im G-J, Tramontano E, Winkler SR, Medina DJ, Dutchman GE, Bazmi HZ, Piras G, Gonzalez CJ and Cheng Y-C, A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 reverse transcriptase confers resistance to TIBO R82150. Mol Pharmacol 43: 11-16, 1993.
117. Balzarini J, Karlsson A, Pérez-Pérez M-J, Vrang L, Walbers J, Zhang H, Öberg B, Vandamme A-M, Camarasa M-J and De Clercq E, HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192: 246-253, 1993.
118. Byrnes V, Blahy O, Condra J, Gotlib L, Graham D, Long W, Quintero J, Rhodes A, Roth E, Sardana V, Schlabach A, Schleif W, Schneider C, Titus D, Wolanski B, Wolfgang J and Emini E, Phenotypic susceptibility of human immunodeficiency virus type 1 RT containing substitutions which engender resistance to nucleoside and non-nucleoside inhibitors. Third Workshop on Viral Resistance, Gaithersburg, Maryland, USA, 1993.
119. Buckheit RW, Kinjerski TL, Fliakas-Boltz V, Russell JD, Stup TL, Pallansch LA, Brouwer WG, Dao DC, Harrison WA, Schultz RJ, Bader JP and Yang SS, Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob Agents Chemother 39: 2718-2727, 1995.
120. Balzarini J, Pérez-Pérez M-J, Vélazquez S, San-Félix A, Camarasa M-J, De Clercq E and Karlsson A, Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc Natl Acad Sci USA 92: 5470-5474, 1995.
121. Balzarini J, Pelemans H, Aquaro S, Perno C-F, Witvrouw M, Schols D, De Clercq E and Karlsson A, Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Mol Pharmacol 50: 394-401, 1996.
122. Balzarini J, Brouwer WG, Dao DC, Osika EM and De Clercq E, Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother 40: 1454-1466, 1996.
123. Zhang H, Vrang L, Backbro K, Lind P, Sahlberg C, Unge T and Öberg B, Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res 28: 331-342, 1995.
124. Ahgren C, Backro K, Bell FW, Cantrell AS, Clemens M, Colacino JM, Deeter JB, Engelhardt JA, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kasher JS, Kinnick MD, Lind P, Lopez C, Morin JM Jr, Muesing MA, Noreen R, Oberg B, Paget CJ, Palkowitz JA, Parrish CA, Pranc P, Rippy MK, Rydergard C, Sahlberg C, Swanson S, Ternansky RJ, Unge T, Vasileff RT, Vrang L, West SJ, Zhang H and Zhou X-X, The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39: 1329-1335, 1995.
125. Moeremans M, De Raeymaeker M, Van den Broeck R, Stoffels P, De Brabander M, De Cree J, Hertogs K, Pauwels R, Staszewski S and Andries K, Virological analysis of HIV-1 isolates in patients treated with the non-nucleoside reverse transcriptase inhibitor R0911767, 8-chloro-TIBO. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 33.
126. Balzarini J, Brouwer WG, Felauer EE, De Clercq E and Karlsson A, Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res 27: 219-236, 1995.
127. Demeter L, Resnick L, Nawaz T, Timpone JG Jr, Batts D and Reichman RC, Phenotypic and genotypic analysis of atevirdine (ATV) susceptibility of HIV-1 isolates obtained from patients receiving ATV monotherapy in a phase I clinical trial (ACTG 187): Comparison to patients receiving combination therapy with ATV and zidovudine. Third Workshop on Viral Resistance, Gaithersburg, Maryland, USA, 1993.
128. Fan N, Rank KB, Evans DB, Thomas RC, Tarpley WG and Sharma SK, Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. FEBS Lett 370: 59-62, 1995.
129. Demeter LM, Shafer RW, Para M, Morse G, Freimuth W, Merigan TC and Reichman RC, Delavirdine (DLV) susceptibility of HIV-1-isolates obtained from patients (PTS) receiving DLV monotherapy (ACTG 260). Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 23.
130. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, Emini EA and Goldman ME, Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 65: 4887-4892, 1991.
131. Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, Anderson KW, Massari FE, Shaw GM and the L-697,661 Working Group, A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 329: 1065-1072, 1993.
132. Staszewski S, Miller V, Kober A, Colebunders R, Vandercam B, Delescluse J, Clumeck N, Van Wanzeele F, De Brabander M, De Cree J, Moeremans M, Andries K, Boucher C, Stoffels P and Janssen PAJ, Evaluation of the efficacy and tolerance of RO18893, RO89439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther 1: 42-50, 1996.
133. Seki M, Sadakata Y, Yuasa S and Baba M, Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442. Antiviral Chem Chemother 6: 73-79, 1995.
134. Yang SS, Pattabiraman N, Gussio R, Pallansch L, Buckheit RW Jr and Bader JP, Cross-resistance analysis and molecular modeling of non-nucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus. Leukemia 11 (Suppl 3): 89-92, 1997.
135. Borroto-Esoda K, Noel DS, Moxham CP and Furman PA, preliminary genotypic analysis of HIV-1 in plasma from volunteers receiving repeated multiple doses of MKC-422. Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 22.
136. Balzarini J, Karlsson A and De Clercq E, Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol Pharmacol 44: 694-701, 1993.
137. Kleim JP, Winkler I, Rosner M, Kirsch R, Rubsamen-Waigmann H, Paessens A and Reiss G, Different mutational pathways of the HIV-1 RT gene are defined by alternative experimental protocols applied to generate in vitro resistance of HIV-1 to HBY 097. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 15.
138. Kleim JP, Winkler I, Rosner M, Kirsch R, Rubsamen-Waigmann H, Paessens A and Reiss G, In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure on the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 231: 112-118, 1997.
139. Vandamme A-M, Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection. Verh K Acad Geneeskd Belg 56: 231-265, 1994.
140. De Clercq E, The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38: 153-179, 1998.
141. Balzarini J, Velazquez S, San-Félix A, Karlsson A, Pérez-Pérez M-J, Camarasa MJ and De Clercq E, Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2′,2′-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type-1-specific non-nucleoside analogues. Mol Pharmacol 43: 109-114, 1993.
142. Balzarini J, Karlsson A, Vandamme A-M, Pérez-Pérez M-J, Zhang H, Vrang L, Öberg B, Bäckbro K, Unge T, San-Félix A, Velázquez S, Camarasa MJ and De Clercq E, Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tertbutyldimethylsilyl)-3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2′,2′-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors. Proc Natl Acad Sci USA 90: 6952-6956, 1993.
143. Balzarini J, Jonckheere H, Harrison WA, Dao DC, Anné J, De Clercq E and Karlsson A, Oxathiin carboxanilide derivatives: A class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem Chemother 6: 169-178, 1995.
144. Vandamme A-M, Schmit JC, Balzarini J, Van Laethem K, Witvrouw M, Hermans P, Sprecher S, Martinez-Picado J, Clotet B, Peetermans W, Desmyter J and De Clercq E, Presence of TSAO-resistant virus strains in non-experienced patients. Fifth Int Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July 1996, Abstract No. 47.
145. Vandamme A-M, Debyser Z, Pauwels R, De Vreese K, Goubau P, Youle M, Gazzard B, Stoffels PA, Cauwenbergh GF, Anné J, Andries K, Janssen PAJ, Desmyter J and De Clercq E, Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res Hum Retroviruses 10: 39-46, 1994.
146. Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna PM and Mellors JW, Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob Agents Chemother 38: 2409-2414, 1994.
147. Staszewski S, Miller V, Rehmet S, Stark T, De Cree J, De Brabander M, Peeters M, Andries K, Moeremans M, De Raeymaeker M, Pearce G, Van den Broeck RM, Verbiest W and Stoffels P, Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 10: F1-F7, 1996.
148. Mellors JW, Dutchman GE, Im JG-J, Tramontane E, Winkler SR and Cheng Y-C, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 41: 446-451, 1992.
149. Richman D, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S and Griffin J, Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 88: 11241-11245, 1991.
150. Kinjerski TL, Pallansch LA and Buckheit RW Jr, Isolation and characterization of HIV-1 isolates resistant to oxathiin carboxanilide analogues: Evaluation of variables in the drug resistance selection process. Antiviral Chem Chemother 7: 261-269, 1996.
151. Maass G, Immendoerfer U, Koening B, Leser U, Mueller B, Goody R and Pfaff E, Viral resistance to the thiazolo-isoindolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37: 2612-2617, 1993.
152. Balzarini J, Karlsson A, Sardana VV, Emini EA, Camarasa M-J and De Clercq E, Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C→C181I)rt HIV-1 mutants. Proc Natl Acad Sci USA 91: 6599-6603, 1994.
153. Sharma SK, Fan N, Bank KB, Kopta LA, Olmsted RA, Poppe SM, Slade DE, Thomas RC and Tarpley WG, A drug resistance mutation (G190E) in the inhibitor binding pocket impairs both RNA-dependent DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 2.
154. Olmsted RA, Slade DE, Kopta LA, Poppe SM, Poel TJ, Newport SW, Rank KB, Biles C, Morge RA, Dueweke TJ, Yagi Y, Romero DL, Thomas RC, Sharma SK and Tarpley WG, (Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J Virol 70: 3698-3705, 1996.
155. Kleim J-P, Bender R, Kirsch R, Meichsner C, Paessens A, Rösner M, Rübsamen-Waigmann H, Kaiser R, Wichers M, Schneweis KE, Winkler I and Riess G, Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 39: 2253-2257, 1995.
156. Kleim J-P, Bender R, Billhardt U-M, Meichsner C, Riess G, Rösner M, Winkler I and Paessens A, Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother 37: 1659-1664, 1993.
157. Moeremans M, De Raeymaker M, Van den Broeck R, Stoffels P and Andries K, Genotypic analysis of HIV-1 isolates from patients receiving loviride alone or in combination with nucleoside reverse transcriptase inhibitor. Fourth Int Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995, Abstract No. 34.
158. Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme A-M, Karlsson A, De Clercq E, Kleim J-P and Balzarini J, characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol 71: 8195-8203, 1997.
159. Pelemans H, Esnouf RM, Parniak MA, Vandamme A-M, De Clercq E and Balzarini J, A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. J Gen Virol 79: 1347-1352, 1998.
160. Balzarini J, Pelemans H, Esnouf R and De Clercq E, A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res Hum Retroviruses 14: 255-260, 1998.
161. Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao Q, Chen SY, Stevenson M and Tarpley WG, A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 90: 4713-4717, 1993.
162. Balzarini J, Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme A-M, Karlsson A, De Clercq E and Kleim J-P, Significance of the 225 Pro → his mutation in HIV-1 reverse transcriptase. Int Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, USA, 25-28 June 1997, Abstract No. 21.
163. Öberg B, Ahgren C, Benthin R, Böttiger D, Classon B, Cox S, Engelhardt P, Ekelöf K, Harmenberg J, Högberg M, Johansson NG, Kangasmetsä J, Lind P, Noréen R, Pelcman M, Rydergard C, Sahlberg B-L, Sahlberg C, Überla K, Vrang L, Zhang H and Zhou X-X, PETT-4, new potent allosteric inhibitors of HIV-1 reverse transcriptase. Eleventh Int Conference on Antiviral Research, San Diego, California, USA, 5-10 April 1998, Abstract No. 4.
164. De Clercq E and Balzarini J, Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: A paradigm for the cure of AIDS. Il Farmaco 50: 735-747, 1995.
165. Cherrington JM, Mulato AS, Lamy PD, Margot NA, Anton KE and Miller MD, Adefovir dipivoxil (bis-POM PMEA) therapy significantly decreases HIV RNA in patients with high-level zidovudine/lamivudine-resistant HIV. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 4.
166. Miller MD, Anton KE, Mulato AS, Lamy PD, Margot NA and Cherrington JM, HIV-1 expressing the lamivudine-associated M184V mutation in reverse transcriptase (RT) shows increased susceptibility to adefovir and PMPA as well as decreased replication capacity in vitro. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 34.
167. Lie YS, Winslow G, Limoli K, Parkin N, Wrin T, Tian T, Smith D, Petropoulos CJ and Whitcomb JM, Resistance profiles to non-nucleoside reverse transcriptase inhibitors determined using a novel phenotypic drug susceptibility assay for HIV-1: Role of mutations at amino acids 225 and 236. 1988 Meeting on Retroviruses, Cold Spring Harbor, New York, USA, 26-31 May 1998, Abstract p. 365.
168. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA and Cameron JM, High-level resistance to (-) enantiomeric 2′deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37: 2231-2234, 1993.
169. Larder BA, 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 36: 2664-2669, 1992.
170. Byrnes VW, Emini EA, Schleif WA, Condra JH, Schneider CL, Long WJ, Wolfgang JA, Graham DJ, Gotlib L, Schlabach AJ, Wolanski BS, Blahy OM, Quintero JC, Rhodes A, Roth E, Titus DL and Sardana VV, Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother 38: 1404-1407, 1994.
171. Eron JJ, Chow Y-K, Caliendo AM, Videler J, Devore KM, Cooley TP, Liebman HA, Kaplan JC, Hirsch MS and D'Aquila RT, Pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother 37: 1480-1487, 1993.
172. Yerly S, Kaiser L, Race E, Clavel F and Perrin L, Reverse transcriptase and protease gene analysis at the time of primary HIV-1 infection. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 107.
173. Balzarini J, Pelemans H, Riess G, Roesner M, Winkler I, De Clercq E and Kleim J-P, Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine. J Infect Dis 176: 1392-1397, 1997.
174. Balzarini J, Pelemans H, Riess E, Roesner M, Winkler I, De Clercq E and Kleim J-P, Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) by an azido-thymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine). Biochem Pharmacol 55: 617-625, 1998.
175. Aquaro S, Perno C-F, Balestra E, Balzarini J, Cenci A, Francesconi M, Panti S, Serra F, Villani N and Caliò R, Inhibition of replication of human immunodeficiency virus in primary monocyte-macrophages by different antiviral drugs, and comparative efficacy in lymphocytes. J Leukoc Biol 62: 138-143, 1997.
176. Gao W-Y, Johns DG and Mitsuya H, Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 46: 767-772, 1994.
177. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J and Gallo RC, Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266: 801-805, 1994.
178. Malley SD, Grange JM, Hamedi-Sangsari F and Vila JR, Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 343: 1292, 1994.
179. Gao W-Y, Johns DG, Chokekijchai S and Mitsuya H, Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 92: 8333-8337, 1995.
180. Gao W-Y, Cara A, Gallo RC and Lori F, Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 90: 8925-8928, 1993.
181. Meyerhans A, Vartanian J-P, Hultgren C, Plikat U, Karlsson A, Wang L, Eriksson S and Wain-Hobson S, Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 68: 535-540, 1994.
182. Matthews CK and Ji J, DNA precursor asymmetries, replication fidelity, and variable genome evolution. Bioessays 14: 295-301, 1992.
183. Palmer S, Shafer R and Merigan TC, Both nucleoside and nucleotide analogues are potentiated by hydroxyurea against drug-susceptible and drug-resistant HIV isolates. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 3.
184. Giacca M, Borella S, Calderazzo F, Bianchi LC, D'Agaro P, Rampazzo C, Bianchi V and Reichard P, Synergistic antiviral action of ribonucleotide reductase inhibitors and 3′-azido-3′-deoxythymidine on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses 12: 677-682, 1996.
185. Hengstschläger M, Denk C and Wawra E, Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control. FEBS Lett 321: 237-240, 1993.
186. Mitchell BS, Song JJ, Johnson EE II, Chen E and Dayton JS, Regulation of deoxycytidine kinase expression. Adv Enzyme Regul 33: 61-68, 1993.
187. Karlsson A, Reichard P and Eckstein F, Hydroxyurea increases the phosphorylation of 3′-fluorothymidine and 3′-azidothymidine in CEM cells. Eur J Biochem 186: 689-694, 1989.
188. Palmer S and Cox S, Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother 41: 460-464, 1997.
189. Vila J, Biron F, Nugier F, Vallet T and Peyramond D, 1-Year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 348: 203-204, 1996.
190. Lori F, Jessen H, Foli A and Lisziewicz L, Long-term suppression of HIV-1 by hydroxyurea and didanosine. J Am Med Assoc 277: 1437-1438, 1997.
191. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange F, Malley S, Hamedi-Sangsari F and Vila J, Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr 10: 36-40, 1995.
192. Lori F, Malykh AG, Foli A, Masersti R, De Antoni A, Wainberg MA and Lisziewicz J, Overcoming drug resistance to HIV-1 by the combination of cell and virus targeting. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, USA, 1997, Abstract No. 173.
193. De Antoni A, Foli A, Lisziewicz J and Lori F, Analysis of mutations of HIV-1 reverse transcriptase after therapy with ddI plus hydroxyurea. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, USA, 1997, Abstract No. 174.
194. Lori F, Jessen H, Maserati R, Seminari E, Foli A and Lisziewicz J, Hydroxyurea-containing combinations exhibit long-term efficacy and a novel resistance/rebound profile. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 149.
195. Johns DG and Gao W-Y, Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 55: 1551-1556, 1998.
196. Milles S, Winters RE and Ruane P, Salvage of multi-drug resistant HIV infections with D4T/3TC/hydroxyurea. 12th World AIDS Conference, Geneva, Switzerland, 28 June-3 July 1998, Abstract No. 288*/12205.
197. Balzarini J, Cooney DA, Dalai M, Kang G-J, Cupp JE, De Clercq E, Broder S and Johns DG, 2′,3′-Dideoxycytidine: Regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 32: 798-806, 1987.
198. Ahluwalia GS, Gao W-Y, Mitsuya H and Johns DG, 2′,3′-Didehydro-3′-deoxythymidine: Regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Mol Pharmacol 50: 160-165, 1996.
199. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E and Desmyter J, Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 31: 1613-1617, 1987.
200. Balzarini J, Herdewijn P and De Clercq E, Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo. Antiviral Res 11: 161-172, 1989.
201. Balzarini J, Naesens L, Robins MJ and De Clercq E, Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J Acquir Immune Defic Syndr 3: 1140-1147, 1990.
202. Balzarini J, Lee C-K, Herdewijn P and De Clercq E, Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J Biol Chem 266: 21509-21514, 1991.
203. Ahluwalia G, Cooney DA, Bondoc LL Jr, Currens MJ, Ford H, Johns DG, Mitsuya H and Fridland A, Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2′,3′-dideoxyguanosine. Biochem Biophys Res Commun 171: 1297-1303, 1990.
204. Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S and Johns DG, Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol Pharmacol 40: 118-124, 1991.
205. Johnson MA and Fridland A, Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol Pharmacol 36: 291-295, 1989.
206. Vogt MW, Hartshorn KL, Furman PA, Chou T-C, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT and Hirsch MS, Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235: 1376-1379, 1987.
207. Balzarini J, Karlsson A, Velazquez S, Pérez-Pérez M-J, San-Félix A, Alvarez R, Perno C-F, Hatse S, Esnouf R, De Clercq E and Camarasa M-J, Shifts in the endogenous 2′-deoxynucleotide pools affect the selection of mutant HIV strains resistant to non-nucleoside reverse transcriptase inhibitors. Second Int Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998, Abstract No. 26.
208. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, Song Q, Manne J, Islam S, Castriota G and Prasad VR, Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271: 1282-1285, 1996.
209. Preston BD, Reverse transcriptase fidelity and HIV-1 variation. Science 275: 228-229, 1997.
210. Drosopoulos WC and Prasad VR, Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro. J Virol 72: 4224-4230, 1998.
211. Wei S, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS and Shaw GM, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122, 1995.
212. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126, 1995.
213. Coffin JM, HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 267: 483-489, 1995.
214. Keulen W, Nijhuis M, Schuurman R, Berkhout B and Boucher C, Reverse transcriptase fidelity and HIV-1 variation. Science 275: 229, 1997.
215. Balzarini J, Pelemans H, De Clercq E, Karlsson A and Kleim J-P, Reverse transcriptase fidelity and HIV-1 variation. Science 275: 229-230, 1997.
216. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang Z-Q, Mills R, McDade H, Goudsmit J, Danner SA and Haase AT, Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960-964, 1998.
217. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M and Ho DD, Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191, 1997.
218. Cohen J, Exploring how to get at - and eradicate - hidden HIV. Science 279: 1854-1855, 1998.
219. Ho DD, Toward HIV eradication or remission: The tasks ahead. Science 280: 1866-1867, 1998.